Open Access

Treatment of Saos‑2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression

  • Authors:
    • Wen‑Peng Xie
    • Yue Zhang
    • Yong‑Kui Zhang
    • Gang Li
    • Jian Xin
    • Rong‑Xiu Bi
    • Chuan‑Jie Li
  • View Affiliations

  • Published online on: April 5, 2018     https://doi.org/10.3892/etm.2018.6037
  • Pages: 4737-4742
  • Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diallyl trisulfide (DATS) is a natural organic sulfur compound that may be isolated from garlic and has strong anticancer activity. DATS has been demonstrated to upregulate the expression of calreticulin (CRT) in various types of human cancers, which is associated with the prognosis of cancer and its response to therapy. However, whether DATS has the same effect on human osteosarcoma cells is not known. Therefore, in the present study, Saos‑2 human osteosarcoma cells were cultured with different concentrations of DATS (0, 25, 50 and 100 µmol/l) for 24 h, or with 50 µmol/l DATS for different time periods (0, 12, 24 and 36 h). Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), western blotting and immunofluorescent staining were used to detect CRT mRNA and protein in the Saos‑2 cells. Exposure to DATS changed the morphology and inhibited the growth of the Saos‑2 cells, and its effects appeared to be concentration‑ and exposure time‑dependent. The optimum concentration and exposure time of DATS were 50 µmol/l and 24 h, respectively. The levels of CRT mRNA and protein in the Saos‑2 cells were significantly upregulated following exposure to DATS. The upregulation of CRT expression by DATS may be a mechanism underlying the ability of DATS to inhibit the growth of human osteosarcoma Saos‑2 cells.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xie WP, Zhang Y, Zhang YK, Li G, Xin J, Bi RX and Li CJ: Treatment of Saos‑2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression. Exp Ther Med 15: 4737-4742, 2018.
APA
Xie, W., Zhang, Y., Zhang, Y., Li, G., Xin, J., Bi, R., & Li, C. (2018). Treatment of Saos‑2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression. Experimental and Therapeutic Medicine, 15, 4737-4742. https://doi.org/10.3892/etm.2018.6037
MLA
Xie, W., Zhang, Y., Zhang, Y., Li, G., Xin, J., Bi, R., Li, C."Treatment of Saos‑2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression". Experimental and Therapeutic Medicine 15.6 (2018): 4737-4742.
Chicago
Xie, W., Zhang, Y., Zhang, Y., Li, G., Xin, J., Bi, R., Li, C."Treatment of Saos‑2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression". Experimental and Therapeutic Medicine 15, no. 6 (2018): 4737-4742. https://doi.org/10.3892/etm.2018.6037